Generic Nurtec ODT Availability
Last updated on Apr 10, 2025.
Nurtec ODT is a brand name of rimegepant, approved by the FDA in the following formulation(s):
NURTEC ODT (rimegepant sulfate - tablet, orally disintegrating;oral)
Is there a generic version of Nurtec ODT available?
No. There is currently no therapeutically equivalent version of Nurtec ODT available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nurtec ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Rimegepant for CGRP related disorders
Patent 11,083,724
Issued: August 10, 2021
Inventor(s): Coric Vladimir & Croop Robert
Assignee(s): Biohaven Pharmaceutical Ireland DACDisclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.
Patent expiration dates:
- March 25, 2039✓✓
- March 25, 2039✓✓
- March 25, 2039
-
CGRP receptor antagonists
Patent 8,314,117
Issued: November 20, 2012
Inventor(s): Luo Guanglin & Dubowchik Gene M. & Macor John E.
Assignee(s): Bristol-Myers Squibb CompanyThe disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
Patent expiration dates:
- March 9, 2030✓✓✓
- March 9, 2030✓✓✓
- March 9, 2030
-
N
Patent 8,759,372
Issued: June 24, 2014
Inventor(s): Roberts Daniel Richard & Schartman Richard Raymond & Wei Chenkou
Assignee(s): Bristol-Myers Squibb CompanyDisclosed is a hemisulfate salt of Compound (I):
Patent expiration dates:
- February 25, 2033✓✓
- February 25, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- February 27, 2025 - NEW CHEMICAL ENTITY
More about Nurtec ODT (rimegepant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (320)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: CGRP inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
